Ebixa H. Lundbeck A/S · Authorised · authorised 15 May 2002 · ATC N06DX01
Therapeutic indication (EMA)
Treatment of patients with moderate to severe Alzheimer's disease.
Active substance
Memantine
- SFDA 20
- US FDA 46
- EMA 10
- Health Canada 11
- US price lines 9
- NHS prices 7
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DEMENT 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 103.85 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Demax | 10 mg | Film-coated tablet · Oral use | 100 Blister | SAR 179.60 | Generic · Prescription | Abdi Ibrahim Ilac San ve Tic A.S. | Valid |
| EBIXA 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 28 Blister | SAR 115.40 | NCE · Prescription | H. LUNDBECK | Valid |
| EBIXA 20MG FILM COATED TABLETS | 20 mg | Film-coated tablet · Oral use | 28 Blister | SAR 252.35 | NCE · Prescription | H. LUNDBECK | Valid |
| ESPADA 10MG F.C TABLETS | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 83.15 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| ESPADA 20MG F.C TABLETS | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 151.60 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| MARLON 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 91.10 | Generic · Prescription | DAMMAM PHARMA | Valid |
| MARLON 20 mg film-coated tablet | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 166.05 | Generic · Prescription | DAMMAM PHARMA | Valid |
| MEMAXIA 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 91.10 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| MEMENTA 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 28 Blister | SAR 94.50 | Generic · Prescription | Abbott Laboratories GmbH | Valid |
| Marixino | 10 mg | Film-coated tablet · Oral use | 28 Blister | SAR 28.73 | Generic · Prescription | KRKA D D NOVO MESTO | Valid |
| TABIXA 10MG FILM COATED TABLET | 10 mg | Film-coated tablet · Oral use | 28 Blister | SAR 103.85 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| TABIXA 20 mg film-coated tablet | 20 mg | Film-coated tablet · Oral use | 28 Blister | SAR 205.00 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| ZEMENTA 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 101.25 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| ZEMENTA 20 mg film-coated tablet | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 184.50 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| MEMANTEX 10 mg Tablet | 10 mg | Tablet · Oral use | 30 Blister | SAR 35.85 | Generic · Prescription | PHARMASCIENCE INC. | Withdrawn by MAH · Not Marketed |
| MEXIA 10 mg Film-coated Tablet | 10 mg | Film-coated tablet · Oral use | 28 Blister | SAR 28.73 | Generic · Prescription | NOBELFARMA ILAC SAN . VE TIC. A.S. | Withdrawn by MAH · Not Marketed |
| MONTAPINE 10 mg Film-coated Tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 35.85 | Generic · Prescription | APOTEX | Withdrawn by MAH · Not Marketed |
| ZEIMER 10MG F.C.TABLET | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 91.10 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Withdrawn by MAH · Not Marketed |
| ZEMENTA 5 mg film-coated tablet | 5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 75.00 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ALZHEIMER / DEMENTIA; ANXIETY DISORDERS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | DR REDDYS LABS LTD | Prescription | 14 Apr 2010 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | SUN PHARM | Prescription | 5 May 2010 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | AMNEAL PHARMS | Prescription | 10 Apr 2015 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | LUPIN | Prescription | 10 Apr 2015 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | UPSHER SMITH LABS | Prescription | 31 Jul 2015 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | UNICHEM | Prescription | 13 Oct 2015 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | ALEMBIC | Prescription | 13 Oct 2015 |
| MEMANTINE HYDROCHLORIDE | 2MG/ML | solution · oral | MACLEODS PHARMS | Prescription | 13 Oct 2015 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | MACLEODS PHARMS LTD | Prescription | 13 Oct 2015 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 13 Oct 2015 |
| MEMANTINE HYDROCHLORIDE | 2MG/ML | solution · oral | CHARTWELL MOLECULAR | Prescription | 13 Oct 2015 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | PURACAP PHARM LLC | Prescription | 17 Nov 2015 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | AJANTA PHARMA LTD | Prescription | 30 Nov 2015 |
| MEMANTINE HYDROCHLORIDE | 7MG; 14MG; 21MG; 28MG | capsule, extended release · oral | LUPIN | Prescription | 28 Sep 2016 |
| MEMANTINE HYDROCHLORIDE | 7MG; 14MG; 21MG; 28MG | capsule, extended release · oral | RISING | Prescription | 28 Sep 2016 |
| MEMANTINE HYDROCHLORIDE | 7MG; 14MG; 21MG; 28MG | capsule, extended release · oral | AMNEAL PHARMS | Prescription | 12 Oct 2016 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | ZYDUS LIFESCIENCES | Prescription | 10 Jul 2017 |
| MEMANTINE HYDROCHLORIDE | 7MG; 14MG; 21MG; 28MG | capsule, extended release · oral | ZYDUS PHARMS | Prescription | 3 Aug 2017 |
| MEMANTINE HYDROCHLORIDE | 2MG/ML | solution · oral | APOTEX | Prescription | 9 Feb 2018 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | SOMERSET THERAPS LLC | Prescription | 7 May 2018 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | YILING | Prescription | 3 Apr 2020 |
| MEMANTINE HYDROCHLORIDE | 2MG/ML | solution · oral | MEDLEY PHARMS | Prescription | 31 Aug 2020 |
| MEMANTINE HYDROCHLORIDE | 5MG; 10MG | tablet · oral | PURACAP LABS BLU | Prescription | 11 Dec 2020 |
| MEMANTINE HYDROCHLORIDE | 7MG; 14MG; 21MG; 28MG | capsule, extended release · oral | YICHANG HUMANWELL | Prescription | 2 Apr 2021 |
| MEMANTINE HYDROCHLORIDE | 7MG; 14MG; 21MG; 28MG | capsule, extended release · oral | AUROBINDO PHARMA LTD | Prescription | 9 Aug 2021 |
21 more — full table
EMA European Union — centrally authorised medicines
Axura Merz Pharmaceuticals GmbH · Authorised · authorised 17 May 2002 · ATC N06DX01
Therapeutic indication (EMA)
Treatment of patients with moderate to severe Alzheimer's disease.
Memantine Merz Merz Pharmaceuticals GmbH · Authorised · authorised 22 Nov 2012 · ATC N06DX01
Therapeutic indication (EMA)
Treatment of patients with moderate to severe Alzheimer’s disease.
Memantine Mylan Mylan Pharmaceuticals Limited · Authorised · authorised 21 Apr 2013 · ATC N06DX01
Therapeutic indication (EMA)
Treatment of patients with moderate to severe Alzheimer’s disease.
Nemdatine Actavis Group PTC ehf · Authorised · authorised 22 Apr 2013 · ATC N06DX01
Therapeutic indication (EMA)
Treatment of patients with moderate to severe Alzheimer’s disease.
Marixino (previously Maruxa) KRKA, d.d. · Authorised · authorised 28 Apr 2013 · ATC N06DX01
Therapeutic indication (EMA)
Treatment of patients with moderate to severe Alzheimer’s disease.
Memantine ratiopharm Ratiopharm GmbH · Authorised · authorised 12 Jun 2013 · ATC N06DX01
Therapeutic indication (EMA)
Treatment of patients with moderate to severe Alzheimer’s disease
Memantine Accord Accord Healthcare S.L.U. · Authorised · authorised 3 Dec 2013 · ATC N06DX01
Therapeutic indication (EMA)
Treatment of patients with moderate to severe Alzheimer’s disease.
Memantine FGK FGK Representative Service GmbH · Application withdrawn · ATC N06DX01
Therapeutic indication (EMA)
Treatment of Alzheimers disease
Memantine LEK Pharmathen S.A. · Withdrawn · authorised 21 Apr 2013 · ATC N06DX01
Therapeutic indication (EMA)
Treatment of patients with moderate to severe Alzheimer’s disease.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACT MEMANTINE | 02324067 | 10 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| APO-MEMANTINE | 02366487 | 10 MG | TABLET · ORAL | APOTEX INC |
| JAMP-MEMANTINE | 02409887 | 5 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-MEMANTINE | 02409895 | 10 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MEMANTINE | 02443082 | 10 MG | TABLET · ORAL | SANIS HEALTH INC |
| MEMANTINE | 02446049 | 10 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| MINT-MEMANTINE | 02531887 | 10 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| PMS-MEMANTINE | 02321130 | 10 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-MEMANTINE | 02382830 | 5.0 MG | TABLET · ORAL | PHARMASCIENCE INC |
| RIVA-MEMANTINE | 02348950 | 10 MG | TABLET · ORAL | LABORATOIRE RIVA INC. |
| SANDOZ MEMANTINE FCT | 02375532 | 10 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | MEMANTINE 5-10 MG TITRATION PK | $0.37236 | per EA | 22 Oct 2025 |
| US NADAC | MEMANTINE HCL 10 MG TABLET | $0.063 | per EA | 23 Sep 2026 |
| US NADAC | MEMANTINE HCL 2 MG/ML SOLUTION | $0.8106 | per ML | 22 Jul 2026 |
| US NADAC | MEMANTINE HCL 2 MG/ML SOLUTION | $0.36068 | per ML | 23 Sep 2026 |
| US NADAC | MEMANTINE HCL 5 MG TABLET | $0.07926 | per EA | 23 Sep 2026 |
| US NADAC | MEMANTINE HCL ER 14 MG CAPSULE | $0.34512 | per EA | 23 Sep 2026 |
| US NADAC | MEMANTINE HCL ER 21 MG CAPSULE | $0.35626 | per EA | 23 Sep 2026 |
| US NADAC | MEMANTINE HCL ER 28 MG CAPSULE | $0.34223 | per EA | 23 Sep 2026 |
| US NADAC | MEMANTINE HCL ER 7 MG CAPSULE | $0.31233 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Memantine 10mg orodispersible tablets sugar free | £24.99 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Memantine 10mg tablets | £1.09 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Memantine 10mg/ml oral solution sugar free | £7.35 | 50 ml | 1 Oct 2026 |
| NHS Drug Tariff | Memantine 20mg orodispersible tablets sugar free | £49.98 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Memantine 20mg tablets | £1.30 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Memantine 5mg orodispersible tablets sugar free | £12.50 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Memantine 5mg/10mg/15mg/20mg tablets treatment initiation pack | £79.09 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 22 Nov 2019 NAMENDA XR — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 2 Nov 2018 NAMENDA — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Jul 2016 NAMZARIC — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations
Combinations containing Memantine
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.